| GeneLibs

题目:: CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
作者:: Lim(Joline S J),Turner(Nicholas C),Yap(Timothy A)
状态:: 发布时间2016-07-02 , 更新时间 2016-07-02
期刊:: Cancer Discov
摘要:: Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non-small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations. Cancer Discov; 6(7); 697-9. ©2016 AACRSee related article by Patnaik et al., p. 740.
语言:: eng
DOI:: 10.1158/2159-8290.CD-16-0563

文献库文献相关信息